Brief: Burning Rock's Liquid Biopsy Assay Achieved Strong Performance In The FDA-Led Seqc2 Study, With Results Published On Nature Biotechnology
13/04/2021 11:48
April 13 (Reuters) - Burning Rock Biotech Ltd BNR.O :
* BURNING ROCK’S LIQUID BIOPSY ASSAY ACHIEVED STRONG
PERFORMANCE
IN THE FDA-LED SEQC2 STUDY, WITH RESULTS PUBLISHED ON NATURE
BIOTECHNOLOGY
Source text for Eikon: ID:nGNX22PPJM
Further company coverage: BNR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Burning Rock Biotech
See all newsBurning Rock Biotech's Q2 revenue falls, net loss widens on central laboratory weakness
China's Burning Rock Biotech Q1 revenue falls on lower test volumes
China's Burning Rock Biotech Q4 net loss narrows as costs fall
Cancer diagnostics firm Burning Rock Biotech's Q3 revenue rises on pharma R&D growth
Brief: Burning Rock's Oncoguide™ Oncoscreen™ Plus CDX System Now Approved In Japan As A Companion Diagnostic For Capivasertib In Breast Cancer